

Oral bisphosphonate use cuts risk of postimplant revision Sx

October 30 2014



(HealthDay)—For patients undergoing total joint replacement, oral bisphosphonate use is associated with a reduction in the risk of revision surgery, according to a study published in the November issue of *Arthritis & Rheumatology*.

Daniel Prieto-Alhambra, M.D., Ph.D., from the University of Oxford in the United Kingdom, and colleagues conducted a retrospective cohort study within Danish nationwide registries to examine the correlation between bisphosphonate use and implant survival. Patients aged 40 years or older undergoing total joint replacement between 1998 and 2007 were identified. Each of 1,558 bisphosphonate users was matched, using propensity scores, to up to six bisphosphonate nonusers (n = 8,966).

The researchers found that during the follow-up period, 1.73 percent of bisphosphonate users and 4.45 percent of matched nonusers underwent



revision surgery, at a median of 2.61 years after first surgery. Bisphosphonate users had a reduced risk of revision surgery (hazard ratio, 0.41). Patients with the longest duration of treatment and/or the best adherence had the strongest correlation.

"Oral <u>bisphosphonate</u> users have a 59 percent reduced risk of revision surgery," the authors write. "This association is only present when bisphosphonates are started after arthroplasty surgery."

Several authors disclosed financial ties to the pharmaceutical industry.

More information: Abstract

Full Text (subscription or payment may be required)

Copyright © 2014 HealthDay. All rights reserved.

Citation: Oral bisphosphonate use cuts risk of post-implant revision Sx (2014, October 30) retrieved 20 November 2023 from https://medicalxpress.com/news/2014-10-oral-bisphosphonate-post-implant-sx.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.